Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | GRK6 | P43250 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25302211 | 0.83 | NPC1 (0.42) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL22851065 | 0.82 | NPC1 (0.53) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5951738 | 0.81 | ELANE (0.38) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL16244492 | 0.81 | ADORA3 (0.41) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL30871800 | 0.79 | PDE4A (0.39) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL27163129 | 0.79 | ADORA2A (0.50) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2671418 | 0.75 | ADORA3 (0.42) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL21816295 | 0.74 | TSHR (0.42) | ELANENPC1RAB9AALDH1A1LMNA | |
| SCHEMBL27163381 | 0.74 | ADORA3 (0.41) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL23456899 | 0.74 | DGAT1 (0.39) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | InventisBio Co., Ltd. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | InventisBio Co., Ltd. (CN) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | TGFB1, TGFB2, TGFBR1 | ELANE 3920/4885NPC1 1455/4885RAB9A 2299/4885 |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | TGFB1, TGFB2, TGFBR1 | ELANE 3920/4885NPC1 1455/4885RAB9A 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.